Skip to content
A Green Sign – Lifestyle
Author:
Vaxcyte, Inc.
Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update
August 5, 2026
Vaxcyte to Participate in Upcoming Investor Conferences
July 8, 2026
Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults
June 2, 2026
Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference
April 7, 2026
Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
March 23, 2026
Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
March 18, 2026